SI2582689T1 - Nova polimorfna oblika imatinib baze in priprava njenih soli - Google Patents

Nova polimorfna oblika imatinib baze in priprava njenih soli

Info

Publication number
SI2582689T1
SI2582689T1 SI201131164A SI201131164A SI2582689T1 SI 2582689 T1 SI2582689 T1 SI 2582689T1 SI 201131164 A SI201131164 A SI 201131164A SI 201131164 A SI201131164 A SI 201131164A SI 2582689 T1 SI2582689 T1 SI 2582689T1
Authority
SI
Slovenia
Prior art keywords
salts
preparation
polymorphic form
new polymorphic
imatinib base
Prior art date
Application number
SI201131164A
Other languages
English (en)
Inventor
Primoz Benkic
Jaroslav Tihi
Anica Pecavar
Tamara German
Franc Vrecer
Anamarija Vajs
Vida Skrabanja
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of SI2582689T1 publication Critical patent/SI2582689T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SI201131164A 2010-06-18 2011-06-17 Nova polimorfna oblika imatinib baze in priprava njenih soli SI2582689T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SI201000181 2010-06-18
SI201000348 2010-10-27
SI201000398 2010-11-19
SI201100054 2011-02-22
EP11726356.6A EP2582689B1 (en) 2010-06-18 2011-06-17 New polymorphic form of imatinib base and preparation of salts thereof
PCT/EP2011/003025 WO2011157450A1 (en) 2010-06-18 2011-06-17 New polymorphic form of imatinib base and preparation of salts thereof

Publications (1)

Publication Number Publication Date
SI2582689T1 true SI2582689T1 (sl) 2017-05-31

Family

ID=44259640

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131164A SI2582689T1 (sl) 2010-06-18 2011-06-17 Nova polimorfna oblika imatinib baze in priprava njenih soli

Country Status (4)

Country Link
EP (1) EP2582689B1 (sl)
EA (1) EA024088B1 (sl)
SI (1) SI2582689T1 (sl)
WO (1) WO2011157450A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DE00728A (sl) 2012-03-13 2015-08-21 Fresenius Kabi Oncology Ltd
GB201204810D0 (en) * 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
WO2014016848A2 (en) * 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN104974134B (zh) * 2015-05-19 2017-01-18 江苏豪森药业集团有限公司 甲磺酸伊马替尼的精制方法
EA035891B1 (ru) 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
EP3969111A4 (en) 2019-05-16 2023-08-16 Aerovate Therapeutics, Inc. INHALABLE FORMULATIONS FOR KINASE INHIBITION

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (sl) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
TR200504337T1 (tr) 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
AU2003242988A1 (en) 2003-06-06 2005-01-04 Adibhatla Kali Sathya Bhujanga Rao Process for the preparation of the anti-cancer drug imatinib and its analogues
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
TR200701870T1 (tr) 2004-09-02 2007-05-21 Cipla Limited İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
WO2006048890A1 (en) 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
EP1833815B1 (en) 2004-12-30 2010-09-15 Instytut Farmaceutyczny A process for preparation of imatinib base
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US7879860B2 (en) 2005-08-26 2011-02-01 Novartis Ag Delta and epsilon crystal forms of Imatinib mesylate
EP1919893A2 (en) 2006-04-27 2008-05-14 Sicor, Inc. Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
KR20090061068A (ko) 2006-10-26 2009-06-15 시코르, 인크. 이매티닙의 제조 방법
JP5265562B2 (ja) 2006-11-16 2013-08-14 エッフェ．イー．エッセ． ファブリカ イタリアーナ シンテーティチ エッセ．ペー．アー． イマチニブおよびその中間体の調製方法
CA2680249A1 (en) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories, Inc. Imatinib mesylate
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
EP2062885A1 (en) 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
EP2291366A4 (en) * 2008-05-26 2012-06-06 Reddys Lab Ltd Dr PREPARATION OF IMATINIB MESYLATE
WO2009147626A2 (en) 2008-06-06 2009-12-10 Alembic Limited Anhydrous amorphous form of imatinib mesylate
PL215042B1 (pl) 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania imatinibu
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011039782A1 (en) 2009-09-29 2011-04-07 Ind-Swift Laboratories Limited Processes for preparing imatinib and pharmaceutically acceptable salts thereof
US20110306763A1 (en) 2009-12-10 2011-12-15 Shanghai Parling Pharmatech Co., Ltd. Process for the preparation of imatinib and salts thereof

Also Published As

Publication number Publication date
EA201291280A1 (ru) 2013-04-30
EP2582689A1 (en) 2013-04-24
EP2582689B1 (en) 2017-03-01
EA024088B1 (ru) 2016-08-31
WO2011157450A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
SI2582689T1 (sl) Nova polimorfna oblika imatinib baze in priprava njenih soli
IL226477A (en) Salts and polymorphic forms of Aptinib
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HK1199728A1 (en) Polymorphic form of pridopidine hydrochloride
FR22C1023I1 (fr) Forme polymorphe st-246 et procedes de preparation
PL2902384T3 (pl) Postać chlorowodorku iwabradyny
EP2487181A4 (en) ARTIFICIAL BASIC COUPLE FOR THE FORMATION OF SPECIFIC BASIC COUPLES
EP2548859A4 (en) PREPARATION OF METHYL-D3-AMINE AND SALTS THEREOF
EP2648519A4 (en) NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
EP2552447A4 (en) STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
EP2291366A4 (en) PREPARATION OF IMATINIB MESYLATE
IL221471A0 (en) Process for the preparation of alpha form of imatinib mesylate
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2691385A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF IMATINIB AND ITS MESYLATE SALT
ZA201105099B (en) Novel forms of bendamustine free base
PT2751081T (pt) Forma polimórfica de pitavastatina cálcica
PT2571355T (pt) Sal de cloridrato cristalino de darunavir
PL390611A1 (pl) Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
EP2601200A4 (en) PREPARATION FROM PRASUGRELHYDROCHLORIDE
PL2608791T3 (pl) Sposób wytwarzania zasady imatynibu
EP2536705A4 (en) POLYMORPHIC FORMS OF LUBIPROSTON
ZA201207945B (en) Salts of dexlansoprazole and their preparation
ZA201300009B (en) Oral formulation of kinase inhibitors
TWM401345U (en) Improved base of false eyelashes
EP2647632A4 (en) PROCESS FOR PREPARING A MESYLATE OF A-IMATINIB